Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report)'s stock price hit a new 52-week high on Friday . The company traded as high as $5.53 and last traded at $4.93, with a volume of 11033487 shares traded. The stock had previously closed at $3.07.
Organogenesis Trading Down 6.8 %
The stock has a 50-day simple moving average of $3.51 and a two-hundred day simple moving average of $3.29. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm has a market cap of $639.21 million, a PE ratio of -84.00 and a beta of 1.66.
Insiders Place Their Bets
In other Organogenesis news, CEO Gary S. Gillheeney sold 55,615 shares of the business's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the transaction, the chief executive officer now owns 3,044,779 shares of the company's stock, valued at approximately $10,230,457.44. The trade was a 1.79 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 278,116 shares of company stock valued at $991,190. 36.90% of the stock is owned by insiders.
Institutional Investors Weigh In On Organogenesis
Several hedge funds and other institutional investors have recently made changes to their positions in ORGO. Captrust Financial Advisors purchased a new stake in shares of Organogenesis during the 3rd quarter valued at about $36,000. Virtu Financial LLC purchased a new stake in shares of Organogenesis during the 4th quarter valued at about $38,000. Intech Investment Management LLC purchased a new stake in shares of Organogenesis during the 3rd quarter valued at about $43,000. Palumbo Wealth Management LLC purchased a new stake in shares of Organogenesis during the 4th quarter valued at about $65,000. Finally, ProShare Advisors LLC increased its position in shares of Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after purchasing an additional 6,689 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Recommended Stories
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
